INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2016. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $4,069,000 | +22.8% | 187,500 | 0.0% | 0.15% | +15.7% |
| Q2 2018 | $3,313,000 | -16.1% | 187,500 | 0.0% | 0.13% | -24.4% |
| Q1 2018 | $3,947,000 | +45.4% | 187,500 | 0.0% | 0.17% | +36.6% |
| Q4 2017 | $2,715,000 | -8.2% | 187,500 | 0.0% | 0.12% | -10.2% |
| Q3 2017 | $2,959,000 | +27.1% | 187,500 | 0.0% | 0.14% | +16.1% |
| Q2 2017 | $2,329,000 | -24.6% | 187,500 | -1.3% | 0.12% | -33.7% |
| Q1 2017 | $3,088,000 | +7.7% | 190,000 | 0.0% | 0.18% | -7.3% |
| Q4 2016 | $2,867,000 | -1.0% | 190,000 | 0.0% | 0.19% | +5.5% |
| Q3 2016 | $2,896,000 | -60.7% | 190,000 | 0.0% | 0.18% | -66.7% |
| Q2 2016 | $7,376,000 | +41.5% | 190,000 | +1.3% | 0.55% | +24.9% |
| Q1 2016 | $5,213,000 | -46.2% | 187,500 | +4.2% | 0.44% | -40.5% |
| Q4 2015 | $9,682,000 | +34.3% | 180,000 | 0.0% | 0.73% | +25.5% |
| Q3 2015 | $7,207,000 | – | 180,000 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |